跳至主要内容
临床试验/JPRN-jRCT1080223381
JPRN-jRCT1080223381已完成Unknown

Special drug use surveillance of Takecab tablets for prevention of recurrence of gastric/duodenal ulcer in patients receiving non-steroidal anti-inflammatory drugs:long-term use

Takeda Pharmaceutical Company Limited0 个研究点目标入组 1,304 人开始时间: 2016年11月16日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
入组人数
1,304

研究概览

简要总结

There seemed to be no new concerns about the safety and efficacy of Vonoprazan for up to 12 months in patients on NSAIDs.

研究设计

研究类型
Observational

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • Participants with a history of gastric or duodenal ulcers

排除标准

  • - Participants with gastric or duodenal ulcer at initiation of vonoprazan therapy
  • - Participants with active upper gastrointestinal haemorrhage at initiation of vonoprazan therapy
  • - Participants with a history of hypersensitivity to any ingredients of vonoprazan Tablets
  • - Participants receiving atazanavir sulfate or rilpivirine hydrochloride

研究者

相似试验